Litcius/Paper detail

Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation

Marco Salvini, Fabrizio Maggi, C. Damonte, Lorenzo Mortara, Antonino Bruno, Barbara Mora, Marco Brociner, Roberta Mattarucchi, Alessia Ingrassia, Davide Sirocchi, Benedetta Bianchi, Stefania Agnoli, Matteo Gallazzi, Michele Merli, Andrea Ferrario, R Bombelli, Daniela Barraco, Andreina Baj, Lorenza Bertù, Paolo Grossi, Francesco Passamonti

2021Bone Marrow Transplantation13 citationsDOIOpen Access PDF

Topics & Concepts

MedicineImmunogenicityMultiple myelomaTransplantationStem cellVirologyAutologous stem-cell transplantationImmunologySevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Coronavirus disease 2019 (COVID-19)AntibodyInternal medicineInfectious disease (medical specialty)DiseaseGeneticsBiologySARS-CoV-2 and COVID-19 ResearchHematopoietic Stem Cell TransplantationCOVID-19 Clinical Research Studies
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation | Litcius